Ascendis
Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes
Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.
Novo Nordisk Secures $285 Million Biobucks Deal with Ascendis Pharma for Monthly GLP-1 Agonist Development
Novo Nordisk, Ascendis Pharma, GLP-1 agonist, biobucks deal, pharmaceutical development
FDA Approves Sandoz and Ascendis Pharma’s Treatments for nAMD and Hypoparathyroidism
FDA approval, Sandoz, Ascendis Pharma, nAMD, hypoparathyroidism, Yorvipath, TransCon PTH